Annexon, Inc. (ANNX)
ANNXNASDAQ-GSBiotechnology: Pharmaceutical Preparations
$4.16
-0.1100 (-2.58%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $801.92m
- P/E
- –
- EPS, last 4 quarters
- $-1.16
- Dividend yield
- –
- Day range
- –
- 52-week range
- $2.54 to $7.18
- Average volume
- 3.35m
- Previous close
- $4.27
Analysts
6 coveringBuy6 buy, 0 hold, 0 sell
Targets a year out average $19.19, +361.3% from here
Earnings
next estimate $-0.2800Next report
Sep 2025
-8.8%
Dec 2025
+12.5%
Mar 2026
+23.3%
Jun 2026
-21.7%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$57.02m | -$50.26m | -$46.05m | -$57.23m |
| Net income | -$54.92m | -$48.26m | -$44.14m | -$55.35m |
News
8 latest- Annexon, Inc. Reports Third Quarter 2026 Financial Results and Strategic Credit Facility of up to $200 millionFintel · 2 hours ago
- Annexon Eyes Q4 2026 Phase III Readout for Vision-Preserving GA DrugMarketBeat · 6 days ago
- Commit To Buy Annexon At $2, Earn 100% Annualized Using OptionsBNK Invest · 6 days ago
- Tuesday 9/29 Insider Buying Report: ANNX, PDI BNK Invest · Sep 29, 2026
- Annexon (ANNX) Q2 2026 Earnings Call TranscriptThe Motley Fool · Aug 19, 2026
- Annexon Q2 Earnings Call HighlightsMarketBeat · Aug 12, 2026
- Annexon Advances C1q-Targeted Therapies; Tanruprubart BLA Filing And ARCHER II Data On The Horizon RTTNews · Aug 12, 2026
- Top Biotech Gainers: APLM Climbs 22%; IOVA, RCEL On Watch; MANE Gains On Hair Loss Data RTTNews · Jul 15, 2026
The company
Annexon Biosciences (Nasdaq: ANNX) is advancing the next generation platform of targeted immunotherapies for nearly 10 million people worldwide living with serious neuroinflammatory diseases. Our founding scientific approach focuses on C1q, the initiating molecule of a potent inflammatory pathway that when misdirected can lead to tissue damage and loss of function in a host of diseases. Our targeted therapies are designed to stop classical complement-driven neuroinflammation at its source to provide meaningful functional benefit and alter the course of disease. Annexon's mission is to deliver game-changing therapies to patients so that they can live their best lives. To learn more visit annexonbio.com.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- annexonbio.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.